The Clinical Relevance of Chromogranin A as a Biomarker for Gastroenteropancreatic Neuroendocrine Tumors
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., Kooij, P. P., de Herder, W. W., Feelders, R. A., van Eijck, C. H., Esser, J.-P., Kam, B. L., & Krenning, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.066 · Cited by 657
Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis
Kim, T., Tao-Cheng, J.-H., Eiden, L. E., & Loh, Y. P. (2001) · Cell · doi:10.1016/s0092-8674(01)00459-7 · Cited by 414
Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana, D., Nori, F., Piscitelli, L., Morselli-Labate, A. M., Pezzilli, R., Corinaldesi, R., & Tomassetti, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1535 · Cited by 248
Marked increase in gastric acid secretory capacity after omeprazole treatment.
Waldum, H. L., Arnestad, J. S., Brenna, E., Eide, I., Syversen, U., & Sandvik, A. K. (1996) · Gut · doi:10.1136/gut.39.5.649 · Cited by 243
Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours
Nehar, D., Lombard‐Bohas, C., Olivieri, S., Claustrat, B., Chayvialle, J., Penes, M., Sassolas, G., & Borson‐Chazot, F. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02030.x · Cited by 177
Sanduleanu, S., De Bruïne, A., Stridsberg, M., Jonkers, D., Biemond, I., Hameeteman, W., Lundqvist, G., & Stockbrügger, R. W. (2001) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2001.00890.x · Cited by 114
Giusti, M., Sidoti, M., Augeri, C., Rabitti, C., & Minuto, F. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500299 · Cited by 111
Nikou, G. C., Marinou, K., Thomakos, P., Papageorgiou, D., Sanzanidis, V., Nikolaou, P., Kosmidis, C., Moulakakis, A., & Mallas, E. (2008) · Pancreatology · doi:10.1159/000152000 · Cited by 84
Korse, C. M., Bonfrer, J. M. G., Aaronson, N. K., Hart, A. A. M., & Taal, B. G. (2009) · Neuroendocrinology · doi:10.1159/000162876 · Cited by 61
(2009) · doi:10.4166/kjg.2019.73.2.84 · Cited by 11
Cited by
Tang, L. H., Untch, B. R., Reidy, D. L., O'Reilly, E., Dhall, D., Jih, L., Basturk, O., Allen, P. J., & Klimstra, D. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0548 · Cited by 352
Chromogranin A—unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
Gut, P., Czarnywojtek, A., Fischbach, J., Bączyk, M., Ziemnicka, K., Wrotkowska, E., Gryczyńska, M., & Ruchała, M. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.57577 · Cited by 144
“Sensitivity of CgA as a marker of neuroendocrine gastro-entero-pancreatic tumors depends on the location of the original tumor [60, 61], metastatic cancer, especially liver metastases [23, 30, 62, 63], and laboratory methodology: determining cutoff CgA [10, 34, 41, 62] and the use of a particular method for detection…”
BackgroundMethod
Metadata
- Authors
- Lawrence, B., Gustafsson, B. I., Kidd, M., Pavel, M., Svejda, B., & Modlin, I. M.
- Venue
- Endocrinology and Metabolism Clinics of North America
- Publisher
- Elsevier BV
- Published
- 2011-03
- Volume
- 40
- Issue
- 1
- Pages
- 111-134
- ISSN
- 0889-8529 (ISSN-L)
- OpenAlex
- W2084721219
- Cited by
- 169
- References
- 10
- FWCI
- 11.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Clinical Relevance of Chromogranin A as a Biomarker for Gastroenteropancreatic Neuroendocrine Tumors. https://app.cochat.ai/papers/10.1016/j.ecl.2010.12.001
- The paper
- Lawrence, B., Gustafsson, B. I., Kidd, M., Pavel, M., Svejda, B., & Modlin, I. M. (2011). The Clinical Relevance of Chromogranin A as a Biomarker for Gastroenteropancreatic Neuroendocrine Tumors. Endocrinology and Metabolism Clinics of North America. https://doi.org/10.1016/j.ecl.2010.12.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.